Patients with POLE/POLD1 mutated tumors harboring telltale mutational signatures responded better to immune checkpoint blockade therapy than patients harboring wild-type or signature-negative tumors.
[Nature Genetics]
Home Newsletters Human Immunology News Functional Landscapes of POLE and POLD1 Mutations in Checkpoint Blockade-Dependent Antitumor Immunity
